Protagonist Therapeutics, Inc.
PTGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 624.1% | 125.7% | -2.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 58.4% | -150.6% | -481.6% | -449.9% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 63.3% | -131.6% | -479.3% | -458.9% |
| EPS Diluted | 4.23 | -1.39 | -2.52 | -2.65 |
| % Growth | 404.3% | 44.8% | 4.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |